Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced several inducement grants of restricted stock units (RSUs) to new employees. The compensation committee approved RSU grants totaling 238,168 shares across 74 new employees between June and September 2025.
The RSU grants follow a consistent vesting schedule, with 25% of shares vesting after one year and the remaining shares vesting quarterly over the following three years, contingent on continued employment. These grants were made under the Company's Amended and Restated 2019 Inducement Equity Plan.
BridgeBio Pharma (Nasdaq: BBIO) announced positive Phase 2 proof-of-concept results for encaleret in treating post-surgical hypoparathyroidism. The study showed that 80% of participants achieved normal blood and urine calcium levels within 5 days of treatment, compared to 0% on conventional therapy.
The oral therapy demonstrated PTH-independent normalization of calcium levels, with nine participants showing rapid and sustained reduction in fractional excretion of calcium. The drug was well-tolerated with no serious adverse events reported. Based on these promising results, BridgeBio plans to initiate a registrational clinical study in 2026.
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for September 10, 2025, at 8:00 am ET. The webinar will feature Dr. Rachel Gafni, Senior Research Physician at the National Institute of Dental and Craniofacial Research (NIH) and Principal Investigator for the CALIBRATE Phase 3 trial.
The presentation will focus on autosomal dominant hypocalcemia type 1 (ADH1), including disease pathophysiology, unmet medical needs, and the potential of encaleret as a treatment. Executive team members will discuss the ongoing Phase 3 CALIBRATE study, with topline results expected in fall 2025.
BridgeBio Pharma (Nasdaq: BBIO) announced upcoming presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 in Seattle. The company will present Phase 2 data for encaleret in post-surgical hypoparathyroidism through an oral presentation by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research.
Additionally, two poster sessions focusing on skeletal dysplasia research will be presented by Dr. Bhavik Shah, showcasing data on infigratinib's effects on bone growth in hypochondroplasia and skull measures in Crouzon/Pfeiffer Syndromes mouse models.
BridgeBio Pharma (Nasdaq: BBIO) announced significant results from the ATTRibute-CM open label extension study of acoramidis through Month 42. The drug demonstrated a 44% reduction in cardiovascular mortality risk for patients with ATTR-CM. Additional key findings include a 46% hazard reduction in the composite outcome of cardiovascular mortality or first cardiovascular hospitalization.
The study showed that acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, achieved disease stabilization in about 50% of participants compared to less than 20% with placebo at Month 30, as measured by NT-proBNP levels. The drug demonstrated the fastest benefit observed in any Phase 3 ATTR-CM study to date, with results visible in just 3 months.
The data was presented at the European Society of Cardiology Congress 2025 in Madrid, highlighting acoramidis's potential as a transformative therapy for ATTR-CM patients.BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced its participation in three major healthcare investor conferences in September 2025. The management team will host fireside chats at the Wells Fargo Healthcare Conference in Boston (September 3), the Cantor Global Healthcare Conference in New York (September 4), and the Morgan Stanley Global Healthcare Conference in New York (September 8).
Investors can access live webcasts of the presentations through BridgeBio's investor relations website, with replays available for 90 days following each event.
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The company will present additional open-label extension data from the ATTRibute-CM study through one oral presentation and two ePosters.
The presentations include data on cardiovascular mortality reduction at Month 42, NT-proBNP improvements at Month 30, and beneficial effects on NAC ATTR Stage changes. Key presenters include experts from Stanford University, UChicago Medicine, and University College London's Centre for Amyloidosis.
BridgeBio Pharma (Nasdaq: BBIO) reported strong Q2 2025 financial results, with total revenue of $110.6 million, including $71.5 million from Attruby® net product revenue. The company's flagship drug Attruby has gained significant traction with 3,751 unique patient prescriptions from 1,074 unique prescribers.
New analyses from the ATTRibute-CM study reinforced Attruby's clinical profile, showing a 59% relative risk reduction in variant ATTR-CM patients and a 31.6% relative risk reduction in mortality associated with increased TTR stabilization. The company ended Q2 with a strong cash position of $756.9 million.
BridgeBio expects multiple key Phase 3 trial results in fall 2025, including FORTIFY (BBP-418 for LGMD2I/R9) and CALIBRATE (encaleret for ADH1), with PROPEL 3 (infigratinib for achondroplasia) results expected in early 2026.
BridgeBio Pharma (Nasdaq: BBIO) has published a significant genetic analysis study in the American Journal of Human Genetics, examining over 100 unique variants associated with autosomal dominant hypocalcemia type 1 (ADH1). The research revealed that approximately 25,000 people in the US and EU carry ADH1-causing variants, with a frequency of ~3.7 per 100,000 individuals.
The study highlighted that only 20% of individuals with ADH1-linked genetic variants have been properly diagnosed, indicating a substantial gap in disease recognition. Additionally, researchers identified nine novel gain-of-function CASR variants. The company's Phase 3 CALIBRATE trial for encaleret, potentially the first approved therapy for ADH1, is fully enrolled with 71 participants, with topline results expected in H2 2025.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has scheduled its second quarter 2025 financial results conference call for Tuesday, August 5, 2025, at 4:30 pm ET. The company will release its financial results and business updates after market close on the same day.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will be available for 30 days following the event.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
